Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
因塞特(US:INCY) Businesswire·2025-12-18 00:20公司核心动态 - Incyte公司宣布其药物Minjuvi® (tafasitamab)获得欧洲委员会批准，用于治疗复发或难治性滤泡性淋巴瘤 [1] 产品与监管进展 - Minjuvi® (tafasitamab)获得欧洲监管机构批准，适应症为复发或难治性滤泡性淋巴瘤 [1]